Related Experiment Videos
Prophylaxis and treatment of infections complicating abdominal surgery
1Department of Internal Medicine, Mayo Clinic, Rochester, MN 55901.
Abstract:
The suitability of commonly used antimicrobial regimens for prophylaxis in abdominal surgery and treatment of intra-abdominal sepsis is discussed. These various therapies are often limited in their usefulness by the range of microorganisms against which they are effective and thus, to extend the antimicrobial cover, agents may be combined. Some forms of therapy may produce adverse effects in susceptible patients, thus limiting their use to certain groups, or there may be cost constraints. Beta-lactamase-inhibiting compounds appear to offer an optimal combination of a broad spectrum of activity against aerobic and anaerobic microorganisms, minimal toxicity and reasonable cost.
Insights
Beta-lactamase inhibitors offer effective antimicrobial prophylaxis and treatment for abdominal sepsis. These agents provide broad-spectrum coverage against aerobic and anaerobic bacteria with minimal toxicity and reasonable cost.
Area of Science:
- Infectious Diseases
- Surgical Infections
- Antimicrobial Therapy
Background:
- Common antimicrobial regimens for abdominal surgery prophylaxis and intra-abdominal sepsis treatment have limitations.
- Limited spectrum of activity and potential adverse effects restrict the use of some therapies.
- Cost constraints also influence the selection of antimicrobial agents.
Purpose of the Study:
- To evaluate the suitability of antimicrobial regimens for abdominal surgery and intra-abdominal sepsis.
- To identify antimicrobial agents offering optimal combinations of efficacy, safety, and cost.
- To discuss the role of beta-lactamase-inhibiting compounds in this context.
Main Methods:
- Review of existing literature on antimicrobial prophylaxis and treatment in abdominal surgery.
- Analysis of the spectrum of activity, toxicity profiles, and cost-effectiveness of various antimicrobial agents.
- Focus on the properties of beta-lactamase-inhibiting compounds.
Main Results:
- Many current antimicrobial therapies have a narrow spectrum of activity, necessitating combination therapy.
- Adverse effects and cost are significant factors limiting the use of certain antimicrobial regimens.
- Beta-lactamase-inhibiting compounds demonstrate broad-spectrum activity against aerobic and anaerobic microorganisms.
Conclusions:
- Beta-lactamase inhibitors present an optimal choice for antimicrobial prophylaxis and treatment in abdominal surgery and sepsis.
- These agents provide a favorable balance of broad antimicrobial coverage, low toxicity, and cost-effectiveness.
- Their use can extend antimicrobial cover effectively while mitigating risks associated with other therapies.